Qiagen reported after the close of the market on Wednesday that its third quarter revenues grew 11 percent year over year as growth in non-COVID-related product groups tempered an expected decline in COVID-19-related product sales.

Pacific Biosciences said after the close of the market on Tuesday that its third quarter revenues rose 83 percent, driven by growth in sequencing instruments and consumables.

Bruker reported after the close of the market Monday that revenues in the third quarter rose 19 percent year over year.

CareDx reported after the close of the market on Thursday that its third quarter revenues rose 42 percent year over year, thanks largely to a 46 percent increase in testing service revenues during the quarter.

Thermo Fisher Scientific reported before the opening of the market on Wednesday that its third quarter revenues rose 9 percent year over year, thanks to growth across three of its four business segments.

MDxHealth reported on Thursday that its third quarter revenues rose 23 percent year over year, largely due to a 23 percent increase in services revenues during the quarter.

Danaher on Thursday reported a 23 percent year-over-year increase in third quarter revenues, which included a rise of nearly 25 percent in life sciences revenues and of nearly 30 percent in diagnostics revenues.

October 19, 2021, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ) released the third quarter report: sale in the third quarter was 6.613 billion CNY, up 20.25% year on year.

Dublin-based diagnostics firm Trinity Biotech on Thursday reported a 61 percent year-over-year increase in second quarter revenues, driven in part by sales of its PCR viral transport media for SARS-CoV-2 testing.

Biocept reported after the close of the market on Monday that its second quarter revenues increased dramatically year over year, as the cancer diagnostics firm continued its provision of COVID-19 testing.